IDH1 and neoplasm: Moreover, IDH1 mutation-driven mouse models of similar solid tumors do not exhibit tumor regression upon removal of the IDH1 mutation, implying a limited efficacy of IDH1 mutation inhibitors when used as monotherapy in tumors with comparable pathological conditions (Turcan et al., 2018).